Skip to content

US · SLS · BIOTECHNOLOGY

SELLAS Life Sciences Group, Inc. (SLS) intrinsic value and stock valuation

$13.66as of 2026-11-21 · Mkt cap 2.23B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

SELLAS Life Sciences Group, Inc. DCF and intrinsic value

InvestorsCraft values SLS with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from SLS’s statements →

SELLAS Life Sciences Group, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology New York, NY 10036 sellaslifesciences.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$0.00
20112025
Net income
-$-26.86M
20112025
Free cash flow
-$-28.39M
20112025
Total equity
$70.9M+20.4% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$1M$7.6M
Operating income-$-28.27M-$-31.51M-$-37.87M-$-41.95M-$-25.29M
Net income-$-26.86M-$-30.88M-$-37.34M-$-41.3M-$-20.7M
EPSd-$-246.31K-$-504.58K-$-1.34M-$-2.13M-$-1.34M
Operating cash flow-$-28.39M-$-35.4M-$-31.41M-$-23.81M-$-26.02M
Capital expenditure$0.00$0.00-$-5.5M-$-4.5M$0.00
Free cash flow-$-28.39M-$-35.4M-$-36.91M-$-28.31M-$-26.02M
Total assets$78.3M$19.4M$6.22M$20.9M$26.4M
Total debt$1M$1M$910K$940K$810K
Net debt-$-70.89M-$-12.88M-$-1.62M-$-16.18M-$-20.65M
Total equity$70.9M$9.46M-$-7.98M$4.85M$20.4M
Cash and short-term investments$71.9M$13.9M$2.53M$17.1M$21.5M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$1M$7.6M
Cost of revenue$0.00$0.00$0.00$100K$200K
Gross profit$0.00$0.00$0.00$900K$7.4M
Research and development expenses$16M$19.1M$24M$30.3M$21.4M
Selling, general and administrative expenses$12.3M$12.4M$13.9M$12.6M$11.3M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$28.3M$31.5M$37.9M$42.9M$32.7M
Cost and expenses$28.3M$31.5M$37.9M$43M$32.9M
Interest income$1.41M$630K$530K$320K$10K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$0.00$31.5M$37.9M$460K$1.27M
Ebitda-$-26.86M$630K$530K-$-31.49M-$-18.32M
Operating income-$-28.27M-$-31.51M-$-37.87M-$-41.95M-$-25.29M
Total other income/expenses, net$1.41M$630K$530K$650K$4.36M
Income before tax-$-26.86M-$-30.88M-$-37.34M-$-41.3M-$-20.94M
Income tax expense$0.00$0.00$0.00$0.00-$-240K
Net income-$-26.86M-$-30.88M-$-37.34M-$-41.3M-$-20.7M
Weighted average shares outstanding$109.1M$61.2M$27.8M$19.4M$15.5M
Weighted average diluted shares outstanding$109.1M$61.2M$27.8M$19.4M$15.5M
Balance sheet
20252024202320222021
Cash and short-term investments$71.9M$13.9M$2.53M$17.1M$21.5M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$75.2M$16.3M$3.17M$17.8M$23M
Property, plant and equipment, net$960K$930K$860K$870K$720K
Goodwill and intangible assets$1.91M$1.91M$1.91M$1.91M$1.91M
Long-term investments$0.00$0.00$0.00-$-180K$0.00
Total non-current assets$3.13M$3.31M$3.05M$3.19M$3.38M
Total assets$78.3M$19.4M$6.22M$20.9M$26.4M
Accounts payable$2.95M$3.5M$5.64M$3.36M$2.14M
Short-term debt$540K$540K$450K$370K$200K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$7.02M$9.51M$13.7M$15.5M$4.98M
Long-term debt$460K$460K$460K$570K$610K
Deferred revenue, non-current$0.00$0.00$0.00-$-180K$0.00
Total non-current liabilities$460K$460K$460K$580K$1.1M
Capital lease obligations$460K$1M$910K$940K$610K
Total liabilities$7.47M$9.97M$14.2M$16.1M$6.08M
Common stock$10K$10K$0.00$0.00$0.00
Retained earnings-$-274.99M-$-248.12M-$-217.24M-$-179.9M-$-138.6M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$70.9M$9.46M-$-7.98M$4.85M$20.4M
Total investments$0.00$0.00$0.00-$-180K$0.00
Total debt$1M$1M$910K$940K$810K
Net debt-$-70.89M-$-12.88M-$-1.62M-$-16.18M-$-20.65M
Cash flow statement
20252024202320222021
Net income-$-26.86M-$-30.88M-$-37.34M-$-41.3M-$-20.7M
Depreciation and amortization$0.00$0.00$0.00$460K$5.68M
Stock-based compensation$1.96M$1.56M$1.39M$1.73M$1.01M
Change in working capital-$-4.08M-$-6.65M$3.35M$5.64M-$-7.62M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-540K-$-2.14M$2.3M$1.21M-$-2.51M
Net cash provided by operating activities-$-28.39M-$-35.4M-$-31.41M-$-23.81M-$-26.02M
Investments in property, plant and equipment$0.00$0.00-$-5.5M-$-4.5M$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00$0.00-$-5.5M-$-4.5M$0.00
Common stock issued$86.8M$46.2M$22.2M$24M$9.01M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$86.3M$46.8M$22.3M$24.1M$12.1M
Net change in cash$57.9M$11.4M-$-14.6M-$-4.23M-$-13.95M
Cash at end of period$71.9M$14M$2.63M$17.2M$21.5M
Operating cash flow-$-28.39M-$-35.4M-$-31.41M-$-23.81M-$-26.02M
Capital expenditure$0.00$0.00-$-5.5M-$-4.5M$0.00
Free cash flow-$-28.39M-$-35.4M-$-36.91M-$-28.31M-$-26.02M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About SELLAS Life Sciences Group, Inc.

        SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

        CEO
        Angelos Stergiou
        Employees
        13
        Beta
        2.42

        Explore

        Frequently asked questions

        What is the intrinsic value of SELLAS Life Sciences Group, Inc. (SLS)?

        InvestorsCraft does not currently publish an intrinsic value for SLS. How the IC value is calculated.

        Is SLS undervalued?

        InvestorsCraft does not publish an undervaluation signal for SLS at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.